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Abstract
Background: In this study, we used vidagliptin(V) to examine the role of the DDP-IV, incretin system component, in the
activation of different molecular inflammatory cytokines, NF-kB and VCAM-1 to generate a microenvironment that supports
cardiovascular remodeling.
Methods: Male WKY and SHR were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution
during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+V: (5 mg/kg per
day for 6 weeks) (n = 8 each group). Metabolic variables and systolic blood pressure were measured. The TBRAS, eNOS
activity, and NAD(P)H oxidase activity were estimated to evaluate oxidative stress. Cardiac and vascular remodeling were
evaluated. To assess the cytokine, NF-kB and VCAM-1 immunostaining techniques were used.
Results: The FFHR experimental model presents metabolic syndrome criteria, vascular and cardiac remodeling, vascular
inflammation due to increased expression of NF-kB, VCAM-1, and pro-atherogenic cytokines. Chronic treatment with V was
able to reverse total or partiality of variables studied.
Conclusions: Data demonstrated an important effect of DDP-IV in reducing vascular inflammation, accompanied by a
favorable reduction in metabolic and structural parameters.
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Introduction
Several authors recently reported that the incretin system
induces an inflammatory and pro-lipolytic response via the PKA -
NF-kB - IL-1 pathway and impairs insulin sensitivity and glucose
uptake in human adipocytes [1–3]. One of the key mechanisms in
the pathogenesis of diabetes-related vascular dysfunction is
oxidative stress. Oxidative stress is attributable to excessive
production of reactive oxygen species (ROS) and inflammatory
markers by tumor necrosis factor-alpha (TNF-alpha), macrophage
chemotactic protein-1 (MCP-1) and other markers [4]. The
inflammatory response was reported to downregulate eNOS
expression and upregulate iNOS expression in rodents and
increase NAD(P)H oxidase activity and vascular remodeling [4–6].
Inhibitors of dipeptidyl peptidase-4 (DPP-IV), a key regulator of
the actions of the incretin hormones, exert anti-hyperglycemic
effects in type 2 diabetic patients. Long-term inhibition of DDP-IV
may reduce pancreatic mass loss due to a reduction in
inflammation induced by oxidative stress [7–8].
Spontaneously hypertensive rats (SHR) provide a model of
genetic hypertension that allows the study of primary hyperten-
sion. The administration of carbohydrate-rich diets to rats can
induce insulin resistance, hyperinsulinemia, dyslipidemia and
moderate hypertension. Chronic fructose-fed rats (FFR) provide
a useful experimental model for studying the interaction of the
factors that shape metabolic syndrome [9]. We postulate that this
dual experimental model could be appropriate for extrapolating
results to human pathology [10].
In the present study, we used vidagliptin to examine the role of
the DDP-IV, incretin system component, in the activation of
different molecular inflammatory cytokines, NF-kB and VCAM-1
to generate a microenvironment that supports cardiovascular
remodeling.
Methods
Animals and experimental design
All procedures were performed according to institutional
guidelines for animal experimentation; the protocol was submitted
and approved by the Institutional Committee for Laboratory
Animal Use and Care (CICUAL) of the School of Medicine-
UNCuyo. Thirty-day-old male Wistar Kyoto (WKY) and SHR
rats were fed a standard commercial chow diet ad libitum and
housed in a room under conditions of controlled temperature
(20uC) and humidity with a 12-hour light/dark cycle during a 12-
week experimental period. Vidagliptin (V) was administered to the
respective groups during the last six weeks of the study.
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I-Control (W): WKY rats receiving food and drinking water (DW)
ad libitum;
II-SHR rats receiving food and DW ad libitum;
III-Fructose-fed Rats (FFR): WKY rats receiving a 10% (w/v)
fructose (Parafarm, Buenos Aires, Argentina) solution in the DW
during all 12 weeks,
IV-Fructose-fed Hypertensive Rats (FFHR): SHR rats receiving a
10% (w/v) fructose solution in the DW during all 12 weeks;
V-FFHR+V: FFHR receiving 5 mg/kg V by intraesophageal
administration.
At the end of the experimental period, the rats were
anesthetized with sodium pentobarbital (50 mg/Kg ip), blood
samples were taken and the arteries and organs were aseptically
excised for measurements.
Systolic blood pressure measurement
The systolic blood pressure (SBP) was monitored indirectly in
conscious, pre-warmed rats that were mildly restrained by the tail-
cuff method and recorded on a Grass Model 7 polygraph (Grass
Instruments Co., Quincy, MA, USA). The rats were trained in the
apparatus several times before measurement.
Biochemical Determinations
HOMA index and intra-peritoneal glucose tolerance
test. The fasting plasma insulin was assayed using the
ACS:180SE automated chemiluminescence system (Bayer, Ger-
many). The plasma glucose levels were assayed using a commercial
colorimetric method (Wiener Lab., Argentina). The homeostasis
model assessment (HOMA) was used as an index to measure the
degree of insulin resistance; it was calculated using the following
formula: [insulin(mU/mL)6glucose(mmol/L)/22.5] [11].
Three days before the end of the experimental period, a glucose
tolerance test (GTT) was performed. Rats fasted overnight were
slightly anesthetized with pentobarbital, and glucose was admin-
istered (2 g/Kg ip). Blood samples were taken by tail-bleeding at 0,
30, 60 and 90 minutes after injection to determine the plasma
glucose concentration. The total area under the curve was
calculated as mmol/L/90 min.
Assessment of the lipid profile. At the end of the
experimental period, blood samples were drawn from the animals
after fasting for 12 hours. The total plasma cholesterol, HDL
cholesterol and triglycerides were assessed using photocolorimetric
enzymatic methods (Wiener Lab., Rosario, Argentina). The data
are expressed in mmol/L.
Oxidative Stress Determinations
Measurement of plasma thiobarbituric acid-reactive
substances (TBARS). To demonstrate the effect of increased
oxidative stress at the vascular level, plasma lipid peroxidation was
assessed by determining the TBARS concentration. This assay is
based on the reaction between plasma malondialdehyde, a product
of lipid peroxidation, and thiobarbituric acid, as has been
previously described [12]. No correction for sample protein
content was necessary because of the nature of sample [13].
Measurement of vascular NAD(P)H-oxidase activity
The lucigenin-derived chemiluminescence assay was used to
determine the NAD(P)H-oxidase activity in a segment of the
thoracic aorta, as previously described [12]. To assess NAD(P)H-
oxidase activity, NADPH (500 mmol/L) was added and chemilu-
minescence was immediately measured in a liquid scintillation
counter (LKB Wallac Model 1219 Rack-Beta Scintillation
Counter, Finland) set in the out-of-coincidence mode. Time-
adjusted and normalized-to-tissue-weight scintillation counters
were used for the calculations. The measurements were repeated
in the absence and presence of diphenylene iodinium (DPI) (10–
6 mol/L), which inhibits flavin-containing enzymes, including
NAD(P)H oxidase [14–15].
eNOS activity in homogenates of cardiac and arterial
tissue
The activity of Ca2+/calmodulin-dependent endothelial nitric
oxide synthase, (eNOS) was measured in mesenteric artery
Table 1. Metabolic and cardiovascular variables.
Variable WKY FFR SHR FFHR FFHR+V
Fasting glucose (mmol/L) 4.8860.1 6.4460.2* 5.060.2 6.560.2*‘ 4.660.1**
Fasting triglycerides (mmol/L) 0.860.0 1.960.0*# 1.060.0 1.960.1*# 1.060.2**
HOMA (mU/mL
insulin6mmol/L glucose)/22.5
4.0060.2 11.060.1*# 7.160.15* 15.160.5*#‘ 4.160.5**
Area under glucose tolerance
test curve (mmol/L/90 min)
881664 1352621*# 1300635* 1909651*#‘ 801667**
HDL Cholesterol (mg/dl) 21.560.3 13.260.4*# 1961,0* 11.661,5*#‘ 20.261.3**
High-sensitivity C reactive
Protein (mg/dL)
1.560.1 3.560.0 3.160.1 4.560.1*#‘ 1.0160.3**
Systolic blood
pressure (mmHg)
Baseline 10563 10261.0 10361 10563 10562
6 weeks 11061.0 12962.0* 16562* 17263*# 17063*
12 weeks 11261.3 13963.0* 17861*# 18562*#‘ 16061.5**
The above values correspond to metabolic and cardiovascular variables. Symbols indicate:
*p,0.001 vs. WKY;
‘p,0.001 vs. SHR;
#p,0.01 vs. FFR.
**vs. FFHR.
doi:10.1371/journal.pone.0106563.t001
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homogenates and in left-ventricle cardiac tissue based on the
conversion of L-[3H]arginine into L-[3H]citruline. The values
were corrected according to the protein contents in the
homogenates (Bradford method) and the incubation time, and
Table 2. Oxidative stress and morphometric variables.
Variable WKY FFR SHR FFHR FFHR+V
NAD(P)H oxidase activity
(counts/min/mg tissue)
40.566 13365* 16069.1*# 29769.1*#‘ 4269.1*‘**
Arterial eNOS activity
(dpm/mg/prot/min)
85.062 60.162.6* 80.062.1 56.465.7*#‘ 86.461.1**
TBARS (mmol/L) 160.1 2.260.1* 1.6960.1* 2.860.1*#‘ 1.0360.6#‘**
Relative heart weight
(mg/100 g body weight)
22564 29064* 33061.8*# 40064*#‘ 30266**
Myocardiocyte area (mm2) 1682669 2066657* 2222678*# 3242655*#‘ 1788634**
Lumen/media relationship
mesenteric arteries
13.960.3 10.260.5* 8.960.6*# 8.4560.2*# 13.864**
The above values correspond to oxidative stress and morphometric variables. Symbols indicate:
*p,0.001 vs WKY;
‘p,0.001 vs SHR;
#p,0.01 vs FFR.
**vs FFHR.
doi:10.1371/journal.pone.0106563.t002
Figure 1. Cytoplasmatic and nuclear p-65 fraction of NF-kB and VCAM-1 expression in mesenteric arteries detected using WB and
IHC. The upper panel shows a representative WB probed with anti-VCAM-1-FITC and anti-p65-TRITC. The results represent the optical density of the
bands for each group. The lower panel shows microphotographs of mesenteric tissue obtained using a laser ICM 600x.
doi:10.1371/journal.pone.0106563.g001
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the results are expressed as dpm/mg protein/min. The material
obtained from each animal was processed independently [16].
Relative heart weight
To evaluate cardiac hypertrophy, we measured the relative
heart weight (RHW). Briefly, the heart was separated from the
great vessels, placed in a buffered saline solution (PBS), blotted
with tissue paper to remove the blood, and weighed. The total
heart weight was corrected according to the ratio between the
heart weight (milligrams) and 100 grams of the total body weight
before sacrifice.
Tissue preservation
Tissue samples for histopathology were processed as has been
previously reported (14). Samples from all rats were used for these
observations. Anesthetized animals were briefly perfused with PBS
(298 mOsmol/Kg H2O, pH 7.40, 4uC) to remove the blood. The
mesenteric arteries were perfused in vivo with the same solution
through the mesenteric artery for 5 min. For the histological
studies, the arteries were also perfused with a 4% paraformalde-
hyde solution for 10 min and fixed in paraffin. Five-micron-thick
tissue slices were transversely cut across the mesenteric tissue on a
microstate (Microm HM, Germany) and processed for histological
studies. A similar procedure was applied for heart tissue
preservation by aortic retrograde perfusion.
Quantitative Histomorphometry to determine cardiac
hypertrophy
Histomorphological analyses were conducted on slices from the
outer (free) wall of the left ventricle (LV) of the heart. Estimations
of the cardiomyocyte area were made from sections stained with
Masson trichrome solution. Areas with transverse sections of
myofibers were selected. The contour of the fibers was then drawn
manually. The total myocardiocyte area was expressed in square
micrometers (mm2).
Arterial structure
Changes in the structure of the arterial walls were assessed by
measuring the medial layer of the mesenteric arteries. The slices
were dyed and examined as has been previously described (14).
Non-transverse sectioned arteries were excluded from the inves-
tigation. The lumen-to-media ratio (i.e., the ratio of the internal
diameter to the medial thickness) (L/M) was then calculated. Fifty
slices from each animal were processed and analyzed to obtain an
average value for each rat. The average values were then used for
the final analysis.
SDS-PAGE and Immunoblot Analysis
The mesenteric tissue from each rat was washed in PBS, and the
proteins were extracted in cold 20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 10% glycerol, 1% Triton X-100, and a protease
inhibitor mixture (P2714, Sigma). After sonication for 15 s (3 times
with 10-s intervals) and extraction for 30 min at 4uC, the sample
extracts were clarified by centrifugation at 14,0006g for 20 min
and used immediately or stored at –20uC. The proteins were
separated on 10% polyacrylamide slab gels and transferred to
0.22-mm nitrocellulose membranes (GE, Germany). Nonspecific
reactivity was blocked by incubation for 1 h at room temperature
in 5% non-fat dry milk dissolved in washing buffer (PBS, pH 7.6,
0.2% Tween 20). The blots were incubated with anti-p65 and anti-
VCAM-1 antibodies (0.2 mg/mL in blocking solution) for 60 min
at room temperature. Horseradish peroxidase-conjugated goat
anti-rabbit-IgG and swine anti-goat-IgG dissolved in blocking
buffer were used as secondary antibodies (0.25 mg/mL, 45 min at
Figure 2. ChemiArray Rat Lysate Cytokine Antibody Array I Map.
doi:10.1371/journal.pone.0106563.g002
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room temperature). Excess first and second antibodies were
removed by washing 5 times for 5 min in blocking solution.
Detection was accomplished with an enhanced chemilumines-
cence system (ABC, Dako System) and subsequent exposure to
Kodak X-AR film (Eastman Kodak) for 5–30 s.
Immunohistochemistry and digital confocal microscopy
(IHC)
Detection of of transcription factors (WB). A rabbit
antibody against the C-terminus of rat NF-kB p65 subunit [Rel
A] was obtained from Millipore International Inc. (Amsterdam,
Netherlands) (AB1604b), and goat anti-rat VCAM-1 (C-19)
antibody was obtained from Santa Cruz Biotechnology Inc.
(Santa Cruz USA) (sc-1504). Tissue sections were cut at a 3-mm
thickness from paraffin-embedded blocks. The antibodies were
diluted 1:1000. The primary incubations were carried out for 1
hour at 21–22uC, followed by extensive six washes in PBS with
Triton X-100 for 5 min each. The secondary antibodies, anti-
rabbit IgG TR and anti-goat IgG FITC (Sigma-Aldrich), were
diluted in PBS alone according to the manufacturer’s instructions.
The images were collected with Nikon EZ-C1 3.00 software on
a Nikon Diaphot TMD microscope.
Measurement of the concentration of high-sensitive C
Reactive Protein (hs-CRP)
The plasma HS-CRP concentrations were measured using a
turbidimetric assay (Bayer Advia 1650, AG Leverkiusen). The data
are expressed in mg/L.
Cytokine determination by ‘‘ChemiArray’’
The expression of the following cytokines was assessed using the
ChemiArray system (rat antibody arrays) (Chemicon Internation-
al, USA): neutrophil chemotactic cytokine 2 and 3 (CINC-2 and
CINC-3), CX3CL1, monocyte chemotactic protein-1 (MCP-1),
macrophage inflammatory protein-3 alpha (MIP-3 alpha), nerve
growth factor beta (beta-NGF), tissue inhibitor of metalloprotei-
nase-1 (TIMP-1), vascular endothelial growth factor (VEGF),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon gamma (INF-c), interleukin 1 alpha and beta (IL-1a,
IL-1b), interleukin 4, 6 and 10 (IL-4, IL-6, IL-10) LIX, leptin,
tumor necrosis factor alpha (TNF-a). The procedures were carried
out according to the manufacturer’s instructions. Detection was
performed with a chemiluminescence system and subsequent
exposure to Kodak X-AR film (Eastman Kodak) for 5–30 s. The
cytokines were distributed in the membranes according the map
(Table 1).
Figure 3. Detection of cytokines on membrane antibody arrays by chemiluminescence. Duplicate spots in the following locations
represent each cytokine. See Figure 1. The average net light intensity for each pair of cytokine spots detected based on ray-scale levels using US NIH
Image software ver 1.66. Cytokines names: Neutrophil chemotactic cytokine 2 and 3 (CINC-2 and CINC-3), ciliary neurotrophic factor (CNFT),
monocyte chemotactic protein-1 (MCP-1), inflammatory protein macrophage-3 alpha (MIP-3 alpha), nerve growth factor beta (beta-NGF), tissue
inhibitor of metalloproteinase-1 (TIMP-1) and vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor, macrophage (GM-
CSF), interferon gamma (INF-c), interleukin 1 alpha and beta (IL-1a, IL-1b), interleukin 4, 6 and 10 (IL-4, IL-6, IL-10), lipopolysaccharide induced CXC
chemokine (LIX or CXCL5), leptin, tumor necrosis factor alpha (TNF-a).
doi:10.1371/journal.pone.0106563.g003
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Reagents
Unless otherwise noted, all reagents were purchased from Sigma
Chemical Co, MO USA.
Statistical and Data Analysis
The data are expressed as the mean 6 SEM. The statistical
significance of the comparisons between all groups was assessed by
one-way ANOVA followed by the Bonferroni post-test. A two-
sided p value of less than 0.05 was considered significant.
Results
Long-Term DPP-4 Inhibition Improves Metabolic Indexes
and Blood Pressure
Chronic administration of fructose induced several alterations
included in the cluster of risk factors that characterizes MS. The
comparison between the HOMA index and the areas under the
GTT curve indicated that the FFR and FFHR developed glucose
intolerance, as demonstrated by the significantly increased
HOMA index and area values compared to the control rats
(Table 1).
On the other hand, the animals in the FFR and FFHR groups
also showed significant differences in the levels of triglycerides and
HDL-cholesterol when compared to the controls (Table 1). The
SHR, FFR and FFHR groups also showed significant differences
in the levels of hs-CRP when compared to the WKY group. The
FFHR group showed higher hs-CRP levels than the other groups.
V reduced all these variables to the levels of WKY (Table 1).
Table 1 also shows the time-course of the changes in SBP
during the experimental period. By the sixth week, the SBP values
of the FFHR and SHR groups were significantly increased
compared to the control group, and there was an increase in
pressure in the FFR group, which was lower but still significant.
Treatment with V did not return the SBP values to those of the
control animals. These results on the value of blood pressure are
statistically significant but not clinically significant, because the
reduction of this value was not less than 140 mmHg.
Long-Term DPP-4 Inhibition results in the recovery of the
oxidative status
Table 2 shows that NAD(P)H-oxidase activity and the plasma
TBARS concentration was significantly higher in the aortas of
FFHR when compared to those from other groups. In addition, in
the FFHR group, the arterial eNOS activity was significantly
reduced, contributing to a decrease in the production and
consequent bioavailability of nitric oxide (NO).
Administration of V effectively reduced superoxide production
by reducing the activity of NAD(P)H oxidase and TBARS, and it
was also able to normalize the eNOS activity (Table 2).
Furthermore, most likely by inhibiting the activity of NAD(P)H
oxidase, V was also able to achieve these effects, normalizing the
endothelial oxidative status (Table 2).
Table 3. Cytokine release profiles on different experimental models.
Cytokinea Relative levelsb Array Locationc Fold increase for control group (WKY)
d
SHR FFR FFHR FFHR+V
CINC-2 H E1-2 1.18 1.10 2.42 2.35
CINC-3 H F1-2 1.34 1.30 2.74 2.67
CNTF - G1-2 , , , ,
Fractalkine - H1-2 , , , ,
GM-CSF - A4-5 , , , ,
INF-c H B3-4 5.00 4.50 5.90 5.40
IL-1a - C3-4 , , , ,
IL-1b - D3-4 , , , ,
IL-4 - E3-4 , , , ,
IL-6 - F3-4 , , , ,
IL-10 - G3-4 , , , ,
LIX - H3-4 , , , ,
Leptin H A5-6 1.16 1.33 2.10 1.07
MCP-1 H B5-6 1.25 NC 4.00 1.02
MIP-3a H C5-6 1.16 1.33 3.91 3.80
b-NGF H D5-6 2.40 2.40 3.50 3.53
TIMP-1 H E5-6 2.60 1.52 2.50 ,
TNF-a H F5-6 3.19 1.10 3.35 ,
VEGF H G5-6 2.50 NC 3.05 1.05
aName of cytokine.
bRelative levels: -, undetectable; H, high: L, low.
cSee Figure 3 for the location of the duplicate spots in the matrix.
dWhen the control ‘‘,’’ symbol was used to indicate an approximation of zero, the values indicate the fold increase vs. WKY (control group). NC, no change (less than or
equal to the fold change in the WKY group).
doi:10.1371/journal.pone.0106563.t003
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Long-Term DPP-4 Inhibition modifies cardiac and
vascular hypertrophy
The RHW and myocardiocyte area was significantly higher in
the FFR, SHR and FFHR groups than in the control rats,
demonstrating myocardial hypertrophy in these experimental
models (Table 2). The FFHR group always displayed a signifi-
cantly reduced L/M when compared to the corresponding arteries
from the WKY group; this result was also observed in the FFR and
SHR groups. Chronic treatment with V partiality reduced
myocardial hypertrophy and vascular remodeling in the FFHR
model. Table 2.
Effects of DDP-IVi on vascular inflammation
The expression of NF-kB and VCAM-1, two products that
actively participate in vascular inflammation, is shown in Figure 1.
Both molecules were detected by IHC. The expression of these
molecules in the FFHR group increased significantly compared to
the control group (W). The right panel shows a representative
image of a WB for these proteins. The average optical density
significantly increased in mesenteric artery homogenates from the
FFHR and FFR groups compared to the controls. It can be
observed that the distribution of the control load was similar for all
groups.
In IHC images of the vascular wall, the FFHR group shows a
large increase in NF-kB expression at the level of the EC and
VSMC, and VCAM-1 is expressed at the sub-endothelial level. V
reduced the activation and nuclear translocation of NF-kB (p65
fraction) and VCAM-1 expression. This could be explained
because in the FFHR group, nuclear factor NF-kB production was
more important due to the production of superoxides as result of
the insulin-resistance status. This may also be a determining factor
in the reduction of vascular remodeling, as previously shown.
DDP-IV on activation of local cytokines
In FFHR model, we observed a significant increase in the levels
of several cytokines, including the following: CINC2, CINC3,
VEGF, MIP-3, beta-NGF, VEGF, Leptin, TNF-alpha, INF-
gamma and MCP-1 (Figures 2, 3 and Table 3). This finding is the
first evidence of the presence of local inflammation at the vascular
level in an experimental model of insulin resistance, such as
FFHR. This result shows the significant presence of pro-
atherogenic cytokines, such as CINC2, CINC3, VEGF, Leptin,
TNF-alpha, MCP-1 and TIMP-1, as well as others whose role at
the vascular level is unknown, such as MIP-3 and beta-NGF, INF-
gamma and others with anti-atherogenic effects. Table 3.
Chronic treatment with V returned the expression levels of pro-
atherogenic cytokines, including VEGF, Leptin, TIMP-1 and
MCP-1, to control values, and V administration significantly
reduced MIP-3alpha and TNF-alpha, demonstrating the impor-
tant role that the incretin system plays in vascular inflammation in
this experimental model (Table 3).
Discussion
In this article, we demonstrated an important effect of DDP-IV
in reducing vascular inflammation, accompanied by a favorable
reduction in metabolic and structural parameters.
The FFHR experimental model presents hypertension, dyslipi-
demia, insulin resistance, vascular and cardiac remodeling,
inflammation demonstrated by increased hsCRP and vascular
inflammation due to increased expression of NF-kB, VCAM-1 and
pro-atherogenic cytokines. The increased expression of VCAM-1
is a marker of vascular inflammation, vascular permeability and
endothelial dysfunction [17–19].
The inflammatory process identified in this experimental model
has two components: 1- a local component involving an increase
in the levels of nuclear transcription factors with subsequent
activation of the inflammatory cascade, resulting in a strong
presence of cytokines, and level 2– a systemic component involving
increased hepatic synthesis of CRP due to a probable increase of
IL-6 [20–22].
The data suggest that incretin system dysfunction, as happen in
patients with diabetes mellitus or metabolic syndrome, allows
activation of inflammatory response in different levels. With the
consequent creation of a vascular microenvironment that is
conducive to the creation, perpetuation, progression, and desta-
bilization of vascular injury, with either a simple eutrophic
mechanism of vascular remodeling, or the generation of an
atherosclerotic lesion.
A number of mechanisms may underlie these results. Given that
GLP-1 is a physiological substrate of DPP-IV, DPP-IV inhibition
by V may be expected to increase the circulating levels of GLP-1
[23] Several studies have reported beneficial effects of GLP-1 on
the cardiovascular system. In humans, Nikolaidis et al. [24] have
shown that a 72-h infusion of GLP-1 improved left ventricular
function in patients with acute myocardial infarction and systolic
dysfunction after successful reperfusion therapy, an effect that was
observed in both diabetic and nondiabetic patients. The authors
suggested that this observation might be explained by the
insulinotropic and insulinomimetic properties of GLP-1; alterna-
tively, GLP-1 might also improve endothelial function. Studies
have shown that GLP-1 improves endothelium-dependent vascu-
lar responses in the brachial artery while leaving endothelium-
independent responses unaffected in healthy humans and patients
with type 2 diabetes [25–26]. The cardiovascular actions of GLP-1
may occur either directly through the GLP-1 receptor or through
a GLP-1 receptor-independent effect of the degradation product of
GLP-1, GLP-1(9–36) [27].
In addition to GLP-1, DPP-IV also degrades GIP, and
potentially cytokines and certain chemokines (including stromal-
derived factor 1-a). Thus, other substrates of DPP-IV may be
responsible for the improvement in endothelial function. Alterna-
tively, V might improve endothelial function by influencing insulin
and glucose levels. Insulin causes vasodilatation by increasing
endothelial production of NO [28]. Vildagliptin might have a
direct pharmacological, yet unidentified, effect on the endotheli-
um.
The improvement in endothelial function and oxidative stress
could result in a decrease in activation of the inflammatory
process.
Other authors have suggested that the DDP-IV inhibitors may
have anti-inflammatory effects, such as reduced activation of TNF-
alpha during macrophage activation [29].
Our results suggest previously unidentified broad pleiotropic
effects [30] of DDP-IV inhibitors and indicate a potential role of
vascular inflammation modulators, which may allow for the
reduction of the vascular complications of atherosclerosis related
of metabolic syndrome.
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